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metastasisFrom the early roots of modern urology to today, genito-
urinary (GU) cancers have been an important part of the
fields of urology and cancer biology. As medical science has
advanced, newer clinical and basic viewpoints have
impacted the thinking and practice in this important field.
As such, GU oncology has been consistently seen as an area
of rapid evolution both in biological understanding and
clinical care. GU cancers continue to rise in incidence
worldwide. Moreover, they represent a significant portion
of cancer mortality in Asia and the western world. These
facts have been met with some of the boldest and most
important advances in cancer biology and therapy that have
reshaped this field.
The idea of this special issue was conceived one year ago
at joint meeting of the Chinese Urological Association and
the Asian Urological Association in Shanghai. At this
meeting, a special session was convened on the topic of
urological cancer metastasis and therapeutic resistance.
Here, basic and clinical urological scientists and in-
vestigators met and enthusiastically shared their ideas and
discoveries with the goal of improving the future of patient
care through research. We, the guest editors, were greatly
impressed by the quality and depth of the science presented
at the meeting and unanimously agreed to volunteer time
and energy to develop this special issue for the Asian Jour-
nal of Urology (AJU ). In this spirit, we invited some of the
preeminent scientists and clinicians from the United States
and Asia to share their perspectives and successes in their
respective areas of work with the hope of stimulating even
more discoveries with the promise for clinical translation.
We have collected fourteen articles in this special issue
including both original research articles and reviews focused
on clinically-relevant models of prostate, kidney, and
bladder cancers. The articles cover a wide range of topics
currently considered to be of prime interests to the field of
uro-oncology. Topics covered by our contributors range
broadly while retaining great depth. These works include
the three manuscripts on the functionality of the androgen
receptor (AR) and the mechanisms underlying the develop-
ment of therapeutic resistance. Three articles focus on thehttp://dx.doi.org/10.1016/j.ajur.2016.09.008
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and how this may present challenges and new opportunities
for the development of improved therapeutics. Three orig-
inal and review articles using clinically relevant materials to
develop new biomarkers predictive of clinical outcome, new
patient-derived xenografts (PDXs) to study cancer bone
metastasis and ex vivo expanded circulating tumor cells
(CTCs) and the CTC-derived xenografts (CDXs) from liquid
biopsies for personalized oncology. And five highly clinically
translatable reviews focusing on the use of CTCs to study the
progression and evolution of cancer cells in blood, clinical
application of new knowledge learned from urothelial can-
cer, recent advances in the development of immune-based
therapeutics for GU tumors, and new concept of devel-
oping cancer therapeutics based on site of cancer metas-
tasis. As guest editors, we have made significant efforts in
reviewing all of the articles and providing special comments
to provide the readership of AJU with high quality papers
with a particular focus on the translational potential of
these topics from the bench to the bedside.
Dr. Jun Luo [1] is a pioneer who discovered spliced AR-V7
mRNA in CTC as a biomarker predictive of androgen
antagonist therapy in prostate cancer patients. He high-
lighted a number of other noninvasive actionable prog-
nostic biomarkers that could prove to be highly valuable in
seeking further improvement of monitoring clinical re-
sponses of metastatic castration-resistant prostate cancer
(CRPC) patients. Dr. Yun Qiu and her colleague Jin Xu [2]
provided mechanistic insights on the expression and the
role of AR spliced variants in driving the progression of
metastatic CRPC and how they contribute to disease
relapse and therapeutic resistance. Dr. Allen Gao and col-
leagues [3] proposed the concept of adaptive pathways that
enable prostate cancer cells to survive androgen-
deprivation therapy, and they developed new strategies
to overcome therapeutic resistance, particularly in pros-
tate cancer patients who relapsed following therapy with
androgen antagonists.
The question of tumor cell plasticity and heterogeneity is
addressed by three excellently prepared reviews. Dr. Yuzhuoon and hosting by Elsevier B.V. This is an open access article under
nd/4.0/).
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the epithelial immune cell-like transition (EIT), where pros-
tate cancer cells were shown to express molecules conven-
tionally expressed by immune cells, hence evading immune
surveillance and a suppressive microenvironment in human
prostate cancer. Understanding the factors secreted by can-
cer cells could help combat the resistance of GU tumors to-
wards immune checkpoint inhibitors. Dr. Jer-Tsong Hsieh and
his colleagues [5] also presented their novel ideas of aggres-
sive prostate cancer cells that assume pluripotency of stem
cell phenotypes are also the cells that drive drug resistance.
Their review summarizes a number of promising cell surface
targets of stem cells responsible for the maintenance of stem
cell self-renewal are the novel therapeutic targets for
aggressive prostate cancer. Dr. Takashi Kobayashi [6]
reviewed the plasticity of urothelial cancer that assumes
epithelial-mesenchymal transition (EMT) and the cancer
stemness and is closely linked to the metastasis of urothelial
cancer. He suggested that in order to improve the survival of
patients with urothelial cancer, we need to seek better un-
derstanding of the progression and metastasis of urothelial
cancer by developing better models, better insights in regu-
latory biology, and better targets that could lead to improved
treatment of patients with urothelial cancer.
The authors are all keenly aware of the fact that
exploiting clinically relevant materials is a crucial element
to advance new knowledge in GU oncology. Dr. Colm Mor-
rissey and colleagues [7] conducted tissue microarrays using
radical prostatectomy from CRPC patients. They found the
absence of several mismatched repair protein expression is
frequent and a predictor of poor outcome in CRPC patients.
Dr. Christina Jamieson and her colleagues [8] presented an
attractive new PDX model of prostate cancer bone metas-
tasis. Their model has the advantage over the other PDXs in
that the bone metastatic tumor cells can grow in culture as
well in situ generating both osteolytic and osteoblastic
lesions in mouse skeleton in an anatomical regional-
dependent manner. Taking advantage of their original
success in establishing CTCs from mouse model of prostate
cancer metastasis, Dr. Ruoxiang Wang [9] shared his views
and experience on culturing CTCs in a highly reproducible
manner to obtain CTCs and CTC-derived PDXs, or CDXs from
cancer patients. CTCs/CDXs could become the first step of
studying the mechanisms underlying cancer metastasis and
to address the molecular basis of how therapeutic resis-
tance to chemo- and hormonal-therapy may be developed.
Perhaps the best examples linking closely the laboratory-
based technologies could impact clinical care of patients
came from the 5 expert contributors who mastered not only
the knowledge of medical care of GU cancer patients, but
also the cutting-edge of investigational sciences and tech-
nologies. Dr. Edwin Posadas [10] reviewed the advancement
of CTC isolation and enumerationmethods and predicted the
future of personalized oncology will evolve from sensitive
and reliable sequencing and computational technologies and
understanding of the biology of CTCs captured frompatients.
Drs. David McConkey, Colin Dinney, and their colleagues [11]
discussed the relevance of the newly-described intrinsic
basal and luminal subtypes of urothelial cancers to metas-
tasis and the use of neoadjuvant chemotherapy. Dr. Tian
Zhang and colleagues [12] comprehensively reviewed recent
progress in the use of immunologic approaches for thetreatment of metastatic renal cell carcinoma urothelial
carcinoma with agents that block cytotoxic T lymphocytes
associated androgen 4 (CTLA-4), programmed death recep-
tor 1 (PD-1), and programmed death-ligand 1 (PD-L1). They
emphasized that a deeper understanding of the mechanisms
of action of immune checkpoint inhibitors and selection of
patients could further improve the therapeutic responses of
patients to immunologic-based therapy. Drs. Ravi Madan and
James Gulley [13] elegantly summarized the development of
a number of emerging immunotherapies for metastatic
prostate cancer, many of which are under development at
National Cancer Institute in the United States in patients. Dr.
Sumanta Pal and his colleagues [14] highlighted the biology
of renal cell carcinoma and how this biology can lead to
revolutions in the treatment of metastatic renal cell carci-
noma based on the clinical patterns of organic-specific
metastasis of this disease.
We are most grateful to the contributors of this special
issue for lending their time, experience, and passion for their
respective fields and the expert reviews of the submitted
articles by Dr. Stephen Shiao and Dr. Sungyong You. All of our
contributors are thought leaders in their fields ranging from
the bench to the bedside with a single goal in mind: elimi-
nation of death and suffering from cancer.We look forward to
the future with great anticipation as all of the authors who
contributed to this issue are actively reshaping clinical
oncology and cancer biology by exploring new frontiers that
will ultimately help patients diagnosed with GU cancers to
find hope, and ultimately a cure for their disease. Our special
thanks also go to Shasha Wei who communicated diligently
with the guest editors, the authors and the publishers and we
do not believe it is possible to publish this special issue
without her dedication and devotion!
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